Just wondering why not 1  BP to this point have decided to lock in a more than a collaborative clinical partnership, Is DM asking too much, are the BP's not sold on epigentic technology for ZEN3694,  Is it too early for a partnership, BP need more clinical trail data? so many question not enough answers ,

IMO i think if zenith gets a buyout or CVR type deal,  RVX will be sold or partnered very soon after, At least the clinical trials are continuing and ongoing.